Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The primary difference lies in their origin and mechanism
Scientific Background on BPC-157 (Body Protection Compound-157) BPC-157 is a stable synthetic pentadecapeptide derived from a protective protein in human gastric juice
Individuals with impaired absorption may not manifest symptoms for several years as hepatic reserves are slowly exhausted
| |---|---|---|---| | Trimethoprim | OCT2 inhibition | 0.3 to 0.5 mg/dL | Yes, within 48 h of stopping | | Cobicistat | MATE1 inhibition | 0.1 to 0.15 mg/dL | Yes, within 1 to 2 weeks | | Cimetidine | Tubular secretion block | 0.2 to 0.4 mg/dL | Yes, within 3 days | | Drospirenone | Antimineralocorticoid | 0.05 to 0.1 mg/dL | Yes, within 1 cycle | | Creatine (5 to 10 g/d) | Increased creatinine production | 0.3 to 0.8 mg/dL | Yes, within 3 to 4 weeks | | Fenofibrate | Increased creatinine production | 0.1 to 0.2 mg/dL | Yes, within 1 to 2 weeks | Step 2: Order cystatin C Cystatin C is a 13-kDa protein produced by all nucleated cells at a constant rate
Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
Lets put this clearly: This is not a pop in and walk out taller kind of procedure
